United Therapeutics Co. Forecasted to Earn Q4 2024 Earnings of $5.52 Per Share (NASDAQ:UTHR)

United Therapeutics Co. (NASDAQ:UTHRFree Report) – Research analysts at Leerink Partnrs issued their Q4 2024 earnings estimates for United Therapeutics in a research note issued to investors on Monday, February 5th. Leerink Partnrs analyst R. Ruiz forecasts that the biotechnology company will earn $5.52 per share for the quarter. Leerink Partnrs currently has a “Outperform” rating on the stock. The consensus estimate for United Therapeutics’ current full-year earnings is $19.47 per share. Leerink Partnrs also issued estimates for United Therapeutics’ FY2026 earnings at $23.73 EPS and FY2027 earnings at $23.22 EPS.

Several other research analysts have also recently commented on UTHR. Wedbush restated an “outperform” rating and set a $308.00 target price (up previously from $307.00) on shares of United Therapeutics in a report on Thursday, November 2nd. JPMorgan Chase & Co. increased their target price on shares of United Therapeutics from $290.00 to $294.00 and gave the stock an “overweight” rating in a report on Thursday, November 2nd. StockNews.com cut shares of United Therapeutics from a “strong-buy” rating to a “buy” rating in a report on Thursday, February 1st. SVB Leerink began coverage on shares of United Therapeutics in a report on Monday, February 5th. They set an “outperform” rating and a $330.00 target price for the company. Finally, Morgan Stanley reduced their target price on shares of United Therapeutics from $318.00 to $314.00 and set an “overweight” rating for the company in a report on Thursday, November 2nd. Eleven analysts have rated the stock with a buy rating, According to data from MarketBeat, the company presently has a consensus rating of “Buy” and a consensus price target of $301.44.

Read Our Latest Report on United Therapeutics

United Therapeutics Stock Up 0.3 %

United Therapeutics stock opened at $212.34 on Thursday. The stock has a market capitalization of $9.98 billion, a PE ratio of 11.70 and a beta of 0.52. United Therapeutics has a twelve month low of $204.44 and a twelve month high of $261.54. The company has a quick ratio of 4.51, a current ratio of 4.65 and a debt-to-equity ratio of 0.09. The company has a 50 day moving average of $225.47 and a 200-day moving average of $227.98.

Insiders Place Their Bets

In other United Therapeutics news, EVP Paul A. Mahon sold 6,000 shares of the company’s stock in a transaction on Thursday, December 7th. The shares were sold at an average price of $238.89, for a total transaction of $1,433,340.00. Following the sale, the executive vice president now directly owns 36,599 shares of the company’s stock, valued at $8,743,135.11. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. In other news, Director Christopher Causey sold 3,000 shares of the stock in a transaction dated Tuesday, December 12th. The shares were sold at an average price of $249.68, for a total value of $749,040.00. Following the transaction, the director now directly owns 4,585 shares of the company’s stock, valued at $1,144,782.80. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, EVP Paul A. Mahon sold 6,000 shares of the stock in a transaction dated Thursday, December 7th. The shares were sold at an average price of $238.89, for a total transaction of $1,433,340.00. Following the completion of the transaction, the executive vice president now directly owns 36,599 shares in the company, valued at $8,743,135.11. The disclosure for this sale can be found here. Over the last three months, insiders have sold 33,605 shares of company stock valued at $7,676,365. 12.50% of the stock is currently owned by corporate insiders.

Hedge Funds Weigh In On United Therapeutics

Several large investors have recently modified their holdings of UTHR. Great West Life Assurance Co. Can raised its position in shares of United Therapeutics by 8.9% in the first quarter. Great West Life Assurance Co. Can now owns 28,326 shares of the biotechnology company’s stock valued at $5,244,000 after purchasing an additional 2,320 shares during the period. Canada Pension Plan Investment Board increased its position in United Therapeutics by 229.6% during the first quarter. Canada Pension Plan Investment Board now owns 2,063 shares of the biotechnology company’s stock worth $371,000 after acquiring an additional 1,437 shares during the period. Prudential PLC bought a new position in United Therapeutics during the first quarter worth about $1,160,000. Zions Bancorporation N.A. bought a new position in United Therapeutics during the first quarter worth about $66,000. Finally, Covestor Ltd increased its position in United Therapeutics by 187.5% during the first quarter. Covestor Ltd now owns 877 shares of the biotechnology company’s stock worth $157,000 after acquiring an additional 572 shares during the period. 94.08% of the stock is owned by institutional investors.

United Therapeutics Company Profile

(Get Free Report)

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. Its commercial therapies include Remodulin to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Tyvaso, an inhaled solution via ultrasonic nebulizer; Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Remunity Pump, a small, lightweight, durable pump and separate controller; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; Unituxin, a monoclonal antibody for treating high-risk neuroblastoma; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.

Further Reading

Earnings History and Estimates for United Therapeutics (NASDAQ:UTHR)

Receive News & Ratings for United Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for United Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.